Monitor upcoming GFORCE-1 readout in H2 2026 as the primary catalyst; pipeline execution and Phase 2 initiation timeline will drive stock movement more than current financials.
Price Chart
Executive Summary
Monte Rosa reported Q1 2026 collaboration revenue of $4.2M (down 95% YoY from $84.9M) and a net loss of $44.5M vs $46.9M net income a year ago. Despite weak financials, the strong cash position ($671M) and multiple clinical catalysts (MRT-8102 GFORCE-1 readout, Phase 2 starts, Novartis collaboration) keep the focus on pipeline execution rather than near-term revenue.
Key Financial Metrics
Key Facts
- Collaboration revenue of $4.2M in Q1 2026, down from $84.9M in Q1 2025 due to milestone timing
- Net loss of $44.5M, compared to net income of $46.9M in prior year quarter
- Cash & securities of $671.2M at March 31, 2026, up from $382.1M at year-end 2025, following $345M equity offering
- Phase 1 data for MRT-8102 showed 85% CRP reduction in high-CVD-risk subjects; GFORCE-1 readout expected H2 2026
- Multiple Phase 2 starts planned for MRT-8102, MRT-2359, and Novartis collaboration on MRT-6160
- Shares outstanding increased to 84.3M from 65.5M due to January offering
Financial Impact
Revenue decline of $80.7M YoY and net loss swing of $91.4M, but offset by $345M capital raise
Risk Factors
- Failure to meet clinical milestones could significantly erode investor confidence
- Cash burn rate of ~$44M/quarter implies ~3.8 years of runway but requires disciplined spend
- Lumpy collaboration revenue creates earnings volatility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-210298 |
| Document: glue-20260507.htm | 0001193125-26-210298 |
| Document: 0001193125-26-210298-index-headers.html | 0001193125-26-210298 |
| Document: 0001193125-26-210298-index.html | 0001193125-26-210298 |
| Document: 0001193125-26-210298.txt | 0001193125-26-210298 |
| 8-K Data (Synthetic) | 0001193125-26-210298 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | 8-K | $11.26 | awaiting T+60 | — | $10.66 (−5.33%) |
Sep 30, 2026 27d ago | Press Release | $11.26 | awaiting T+60 | — | $10.66 (−5.33%) |
Aug 6, 2026 11w ago | 8-K | $15.71 | awaiting T+60 | — | $10.66 (−32.15%) |
Jul 17, 2026 14w ago | Insider Cluster | $23.48 $9.89 | ▼ −57.88% | ▼ −62.72% | $10.66 (−54.60%) |
Jul 7, 2026 16w ago | Insider Cluster | $24.06 $11.93 | ▼ −50.42% | ▼ −52.73% | $10.66 (−55.69%) |
Jul 1, 2026 16w ago | Insider Cluster | $24.21 $11.72 | ▼ −51.59% | ▼ −54.60% | $10.66 (−55.97%) |
Jul 1, 2026 16w ago | Insider Cluster | $24.21 $11.72 | ▼ −51.59% | ▼ −54.60% | $10.66 (−55.97%) |
Jun 29, 2026 17w ago | 144 | $24.20 $11.89 | ▼ −50.87% | ▼ −54.43% | $10.66 (−55.95%) |
Jun 25, 2026 17w ago | Insider Cluster | $22.29 $12.60 | ▼ −43.47% | ▼ −49.56% | $10.66 (−52.18%) |
Jun 2, 2026 21w ago | Insider Cluster | $17.59 $14.32 | ▼ −18.59% | ▼ −21.09% | $10.66 (−39.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers